FRANKFURT (Reuters) – Germany’s Merck KGaA said on Tuesday the company’s experimental multiple sclerosis drug evobrutinib did not meet the primary goal in highly anticipated late-stage trials.
Phase III trial results for the drug evobrutinib in relapsing multiple sclerosis did not meet the primary endpoint of reducing annualized relapse rates compared to Sanofi’s established pill Aubagio, Merck said in a statement.
(Reporting by Ludwig Burger)
